In patients with advanced heart failure (HF), the dependence on intravenous vasoactive drug support (VDS) is an indicator of end-stage disease associated with a lower probability of response to therapeutic interventions. It has been reported that individuals requiring vasopressors are exposed to an increased risk of right ventricular failure and death following left ventricular assist device (LVAD) implantation [1] , and that preoperative VDS is a risk factor for primary graft failure after heart transplantation (HT) [2] .
The need for high-dose preoperative VDS (VIS ≥ 20) was identified as an independent predictor of increased post-transplant mortality, both in the entire cohort (HR 1.80, 95% CI 1.26-2.56, p = 0.001) and in the subcohorts of patients bridged to HT on an intraaortic balloon (HR 1.71, 95% CI 1.09-2.69, p = 0.019) or on extracorporeal MCS (HR 2.66, 95% CI 1.14-6.23, p = 0.024), but not in medically managed patients (HR 0.94, 95% CI 0.41-2.13, p = 0.881). By means of multivariable logistic regression, a preoperative VIS ≥ 20 was identified as an independent predictor of postoperative infection (odds ratio (OR) 1.66, 95% CI 1.02-2.71, p = 0.041) and in-hospital postoperative mortality (OR 1.95, 95% CI 1.17-3.28, p = 0.011).
This study confirms the hypothesis that the intensity of preoperative VDS correlates with postoperative outcomes in patients undergoing HT, and supports the routine use of the VIS for preoperative risk assessment in this population. In our multi-institutional series, we have observed that candidates requiring high-dose preoperative VDS, defined by a VIS ≥ 20, were exposed to a significantly increased risk of post-transplant mortality, driven by a higher risk of complications and death during the early postoperative period. The adverse prognostic impact of a high preoperative VIS was especially marked among candidates bridged to transplantation under MCS. In these patients, the need for high-dose VDS may reflect an insufficient hemodynamic support -e.g., due to right ventricular failure following LVAD implantation -or other associated conditions such as sepsis, bleeding, tamponade, hypovolemia, or vasoplegia. Whatever the cause is, the resort to emergency HT as a 'bailout' therapy in this clinical scenario is associated with poor clinical outcomes and should be avoided.
